/clinical/,/clinical/cckm-tools/,/clinical/cckm-tools/content/,/clinical/cckm-tools/content/beacon-protocols/,/clinical/cckm-tools/content/beacon-protocols/supportive-care/,

/clinical/cckm-tools/content/beacon-protocols/supportive-care/name-122974-en.cckm

201711331

page

100

UWHC,UWMF,

Tools,

Clinical Hub,UW Health Clinical Tool Search,UW Health Clinical Tool Search,Beacon Protocols,Supportive Care

CSC SC Zoledronic Acid (Reclast) 5 mg Anually (Once) Ver 11-20-17 (HL 1880)

CSC SC Zoledronic Acid (Reclast) 5 mg Anually (Once) Ver 11-20-17 (HL 1880) - Clinical Hub, UW Health Clinical Tool Search, UW Health Clinical Tool Search, Beacon Protocols, Supportive Care


CSC SC ZOLEDRONIC ACID (RECLAST) 5 MG ANUALLY (ONCE) VER: 11-20-17 –  Properties
Cycle 1 –  11/22/2017 through 11/20/2018 (364 days), Planned
Day 1, Cycle 1 –  Planned for 11/22/2017
Treatment Plan Information
Note to All Staff (1)
This supportive care plan is for the zoledronic acid (RECLAST) formulation. It is only approved for use in patients with
senile osteoporosis. If the patient does not have this diagnosis another supportive care plan using zolendronic acid
(ZOMETA) may be more appropriate. The diagnosis for this patient is: ***.
Hydration
sodium chloride 0.9 % infusion
at 20 mL/hr, Intravenous, ONCE, 1 dose Starting when released
To establish line and for flushing.
Supportive Care Medications
zoledronic acid (RECLAST) 5 mg/100 mL bag 5 mg
5 mg, Intravenous, ONCE, 1 dose Starting when released, Administer over 15 Minutes
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
ZZtestonc,Andrew [2428787]
11/22/2017 1:05:44 PM Page 1 of 1
Copyright © 2017 University of Wisconsin Hospitals and Clinics Authority
Contact: Lee Vermeulen, CCKM@uwhealth.org Last Revised: 11/2017CCKM@uwhealth.org